MyIDEAS: Login

Springer Healthcare | Adis

PharmacoEconomics

Contact information of Springer Healthcare | Adis:
Web page: http://pharmacoeconomics.adisonline.com/

To be notified about new items in this series: Register for eTOC http://pharmacoeconomics.adisonline.com/pt/re/phe/etocs.htm (see also NEP)
Download restrictions: Pay per view
Editor:
For corrections or technical questions regarding this series, please contact (Dave Dustin)
Series handle: repec:wkh:phecon
Citations RSS feed: at CitEc
Impact factors: Simple, Recursive, Discounted, Recursive discounted, H-Index, Aggregate
Access and download statistics
Top item: By citations. By downloads (last 12 months).

More pages of listings: 0| 1| 2| 3| 4| 5| 6| 7

2008, Volume 26, Issue 10

892-894 The Authors
by Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman

2008, Volume 26, Issue 6

447-462 Economic Burden of Heart Failure in the Elderly
by Lawrence Liao & Larry A. Allen & David J. Whellan
463-476 Cost of Epilepsy: A Systematic Review
by Adam Strzelczyk & Jens Peter Reese & Richard Dodel & Hajo M. Hamer
477-495 Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada
by Deborah A. Marshall & Patrick R. Douglas & Michael F. Drummond & George W. Torrance & Stuart MacLeod & Orlando Manti & Lokanadha Cheruvu & Ron Corvari
497-511 Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation Model: Application to a Population of US Adult Smokers
by Paul Howard & Christopher Knight & Annabel Boler & Christine Baker
513-536 Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis
by Dirk Mueller & Eva Weyler & Afschin Gandjour

2008, Volume 26, Issue 5

359-361 Cost-Effectiveness Analysis: Developing Nations Left Behind
by Mendel E. Singer
363-370 Perspectives on Patient-Reported Outcomes: Content Validity and Qualitative Research in a Changing Clinical Trial Environment
by Nancy Kline Leidy & Margaret Vernon
371-393 Economic Evaluation of Interventions to Treat Opiate Dependence: A Review of the Evidence
by Christopher M. Doran
395-408 Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States
by Nick Bansback & Roberta Ara & Jonathan Karnon & Aslam Anis
409-423 Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer: A Need for Improved Modelling to Aid Decision Making
by Lieven Annemans
425-434 A Multicentre, Prospective Study to Evaluate Costs of Septic Patients in Brazilian Intensive Care Units
by Ana M.C. Sogayar & Flavia R. Machado & Alvaro Rea-Neto & Amselmo Dornas & Cintia M.C. Grion & Suzana M.A. Lobo & Bernardo R. Tura & Carla L.O. Silva & Ruy G.R. Cal & Idal Beer & Vilto Michels & Jorge Safi & Marcia Kayath & Eliezer Silva
435-446 Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-alpha Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia
by Shelby D. Reed & Kevin J. Anstrom & Yanhong Li & Kevin A. Schulman

2008, Volume 26, Issue 4

269-280 An Overview of Methods and Applications to Value Informal Care in Economic Evaluations of Healthcare
by Marc A. Koopmanschap & N. Job A. van Exel & Bernard van den Berg & Werner B.F. Brouwer
281-296 Making a Case for Employing a Societal Perspective in the Evaluation of Medicaid Prescription Drug Interventions
by Sanjoy Roy & S. Suresh Madhavan
297-310 The Use of QALY Weights for QALY Calculations: A Review of Industry Submissions Requesting Listing on the Australian Pharmaceutical Benefits Scheme 2002-4
by Paul A. Scuffham & Jennifer A. Whitty & Andrew Mitchell & Rosalie Viney
311-328 Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model
by Simon Kreck & Jochen Klaus & Reiner Leidl & Christian von Tirpitz & Alexander Konnopka & Herbert Matschinger & Hans-Helmut Konig
329-339 An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes
by Scott D. Ramsey & Lauren D. Clarke & Craig S. Roberts & Sean D. Sullivan & Scott J. Johnson & Larry Z. Liu
341-358 Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study
by Martin Knapp & Frank Windmeijer & Jacqueline Brown & Stathis Kontodimas & Spyridon Tzivelekis & Josep Maria Haro & Mark Ratcliffe & Jihyung Hong & Diego Novick

2008, Volume 26, Issue 3

179-180 Meandering Down the Road to Transparency
by Christopher I. Carswell & Joseph A. Paladino
181-183 Transparency of Economic Evaluations of Health Technologies
by Joan Rovira
185-189 Projecting Vaccine Efficacy: Accounting for Geographic Strain Variations
by Johnie Rose & Mendel E. Singer
191-215 Cost-Effectiveness Analyses of Vaccination Programmes: A Focused Review of Modelling Approaches
by Sun-Young Kim & Sue J. Goldie
217-234 Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens
by Jeremy Chancellor & Samuel Aballea & Alison Lawrence & Rob Sheldon & Sandrine Cure & Juliette Plun-Favreau & Nick Marchant
235-249 Community and Patient Values for Preventing Herpes Zoster
by Tracy A. Lieu & Ismael Ortega-Sanchez & G. Thomas Ray & Donna Rusinak & W. Katherine Yih & Peter W. Choo & Irene Shui & Ken Kleinman & Rafael Harpaz & Lisa A. Prosser
251-268 Zoledronic Acid: A Pharmacoeconomic Review of its Use in the Management of Bone Metastases
by Kate McKeage & Greg L. Plosker

2008, Volume 26, Issue 2

91-98 Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies
by Brian Godman & Alan Haycox & Ulrich Schwabe & Roberta Joppi & Silvio Garattini
99-120 Management of Anaemia: A Critical and Systematic Review of the Cost Effectiveness of Erythropoiesis-Stimulating Agents
by Mei Sheng Duh & Jennifer R. Weiner & Leigh Ann White & Patrick Lefebvre & Paul E. Greenberg
121-129 Economic Burden of Psoriatic Arthritis
by Christoph Ackermann & Arthur Kavanaugh
131-148 Modelling Methods for Pharmacoeconomics and Health Technology Assessment: An Overview and Guide
by James E. Stahl
149-162 The Burden of Schizophrenia on Caregivers: A Review
by A. George Awad & Lakshmi N.P. Voruganti
163-178 Non-Traditional Settings for Influenza Vaccination of Adults: Costs and Cost Effectiveness
by Lisa A. Prosser & Megan A. O'Brien & Noelle-Angelique M. Molinari & Katherine H. Hohman & Kristin L. Nichol & Mark L. Messonnier & Tracy A. Lieu

2008, Volume 26, Issue 1

1-4 The New Myth: The Social Value of the QALY
by Werner Brouwer & Job van Exel & Rachel Baker & Cam Donaldson
5-15 The Last Decade of Italian Pharmaceutical Policy: Instability or Consolidation?
by Giovanni Fattore & Claudio Jommi
17-32 Cost-Effectiveness Analyses of Hepatitis A Vaccine: A Systematic Review to Explore the Effect of Methodological Quality on the Economic Attractiveness of Vaccination Strategies
by Andrea M. Anonychuk & Andrea C. Tricco & Chris T. Bauch & Ba' Pham & Vladimir Gilca & Bernard Duval & Ava John-Baptiste & Gloria Woo & Murray Krahn
33-44 Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas: A Cost-Utility Analysis
by Gabriel Rogers & Ruth Garside & Stuart Mealing & Martin Pitt & Rob Anderson & Matthew Dyer & Ken Stein & Margaret Somerville
45-56 Dynamic Modelling of Infectious Diseases: An Application to the Economic Evaluation of Influenza Vaccination
by Roberto Pradas-Velasco & Fernando Antonanzas-Villar & Maria Puy Martinez-Zarate
57-73 Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study
by Alan F. Cruess & Gergana Zlateva & Xiao Xu & Gisele Soubrane & Daniel Pauleikhoff & Andrew Lotery & Jordi Mones & Ronald Buggage & Caroline Schaefer & Tyler Knight & Thomas F. Goss
75-90 Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections
by Robin de Vries & Simon Daenen & Keith Tolley & Axel Glasmacher & Archie Prentice & Sarah Howells & Hariette Christopherson & Lolkje T.W. de Jong-van den Berg & Maarten J. Postma

2007, Volume 25, Issue 12

991-993 Acknowledgement
by Adis International Limited
995-996 When NICE Says No!
by Alan Haycox
997-1006 NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors: Was the Right Question Posed? Were the Best Tools Used?
by Denis Getsios & Kristen Migliaccio-Walle & Jaime J. Caro
1007-1029 Recombinant Factor VIIa (Eptacog Alfa): A Pharmacoeconomic Review of its Use in Haemophilia in Patients with Inhibitors to Clotting Factors VIII or IX
by Katherine A. Lyseng-Williamson & Greg L. Plosker
1031-1053 Atorvastatin: A Pharmacoeconomic Review of its Use in the Primary and Secondary Prevention of Cardiovascular Events
by Greg L. Plosker & Katherine A. Lyseng-Williamson
1055-1062 Economic Evidence at the Local Level: Options for Making it More Useful
by Kees van Gool & Gisselle Gallego & Marion Haas & Rosalie Viney & Jane Hall & Robyn Ward
1063-1082 Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events: An Assessment from the Payer's Perspective
by Bart Heeg & Joep Damen & Ben Van Hout

2007, Volume 25, Issue 11

899-902 Warfarin Pharmacogenetics: Economic Considerations
by Dyfrig A. Hughes & Munir Pirmohamed
903-911 It's Time to Choose the Study Design!: Net Benefit Analysis of Alternative Study Designs to Acquire Information for Evaluation of Health Technologies
by Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman
913-933 The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A Structured Review of the Literature
by Rachael L. Fleurence & Cynthia P. Iglesias & Jeanene M. Johnson
935-947 Economic Evaluations of Calcineurin Inhibitors in Renal Transplantation: A Literature Review
by Alec H. Miners & Guiqing Yao & James Raftery & Rod S. Taylor
949-961 Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia: A Cost-Effectiveness Analysis
by Amanda R. Patrick & Wolfgang C. Winkelmayer & Jerry Avorn & Michael A. Fischer
963-977 Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B
by David L. Veenstra & Sean D. Sullivan & Lauren Clarke & Uche H. Iloeje & Eskinder Tafesse & Adrian Di Bisceglie & Kris V. Kowdley & Robert G. Gish
979-990 The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary: Cost-Effectiveness and Budget-Impact Analyses
by Marcio Machado & Michael Iskedjian & Ines A. Ruiz & Thomas R. Einarson

2007, Volume 25, Issue 10

807-816 Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions: Why Uncertainty About the Outcome, Estimate and Willingness to Pay Matters
by Jeffrey S. Hoch & Carolyn S. Dewa
817-828 Valuing Children's Health: A Comparison of Cost-Utility Analyses for Adult and Paediatric Health Interventions in the US
by Joseph A. Ladapo & Peter J. Neumann & Ron Keren & Lisa A. Prosser
829-841 A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD
by Laura Bojke & Edward Hornby & Mark Sculpher
843-862 Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients
by Ya-Chen Tina Shih & Nebiyou B. Bekele & Ying Xu
863-879 Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK
by Sorrel E. Wolowacz & Neil Roskell & Steven Kelly & Fiona M. Maciver & Chris S. Brand
881-897 Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin: Economic Comparison in Adult and Adolescent Type 1 Diabetes Mellitus in Australia
by Neale Cohen & Michael E. Minshall & Lyn Sharon-Nash & Katerina Zakrzewska & William J. Valentine & Andrew J. Palmer

2007, Volume 25, Issue 9

713-726 Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children: Theoretical and Methodological Considerations
by Lisa A. Prosser & James K. Hammitt & Ron Keren
727-734 The Increasingly Complex Fourth Hurdle for Pharmaceuticals
by Joshua Cohen & Elly Stolk & Maartje Niezen
735-750 Modelling Disease Progression in Alzheimer's Disease: A Review of Modelling Methods used for Cost-Effectiveness Analysis
by Colin Green
751-768 Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus: Review and Analysis of the Literature
by Andrew F. Shorr
769-782 Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention
by Bart M.S. Heeg & Ron J.G. Peters & Marc Botteman & Ben A. van Hout
783-792 Preferences of Community Pharmacists for Extended Roles in Primary Care: A Survey and Discrete Choice Experiment
by Anthony Scott & Christine Bond & Jackie Inch & Aileen Grant
793-800 Reliability of Medicaid Claims Versus Medical Record Data: In a Cost Analysis of Palivizumab
by Julie Jacobson Vann & John Feaganes & Steven Wegner
801-802 A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
by Philip Home & Adrian Bagust & Matthew Taylor & Philip Ambery & Samara Mendes da Costa
802-805 The Authors' Reply
by Dominic P. Tilden & Segundo Mariz & Gillies O'Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos

2007, Volume 25, Issue 8

621-635 When Drugs Don't Work: Economic Assessment of Enhancing Compliance with Interventions Supported by Electronic Monitoring Devices
by Dyfrig Hughes
637-648 Impact of Pharmaceutical Prior Authorisation Policies: A Systematic Review of the Literature
by Jaume Puig-Junoy & Ivan Moreno-Torres
649-664 The Contrast and Convergence of Bayesian and Frequentist Statistical Approaches in Pharmacoeconomic Analysis
by Grant H. Skrepnek
665-676 Healthcare Utilisation and Costs Associated with Adding Montelukast to Current Therapy in Patients with Mild to Moderate Asthma and Co-Morbid Allergic Rhinitis: PRAACTICAL Study
by Roberto Dal Negro & Peter Piskorz & Roberto Vives & Magda Guilera & Vasilisa Sazonov Kocevar & Xavier Badia
677-683 Direct Costs in Patients Hospitalised with Community-Acquired Pneumonia After Non-Response to Outpatient Treatment with Macrolide Antibacterials in the US
by Joseph A. Paladino & Martin H. Adelman & Jerome J. Schentag & Paul B. Iannini
685-693 A Stated Preference Binary Choice Experiment to Explore NICE Decision Making
by Paul Tappenden & John Brazier & Julie Ratcliffe & James Chilcott
695-711 A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease
by Maureen P.M.H. Rutten-van Molken & Floortje E. van Nooten & Marion Lindemann & Manfred Caeser & Peter M.A. Calverley

2007, Volume 25, Issue 7

533-535 Perspectives on Dynamic Optimisation and Control Theory in Treating Hyperlipidaemia
by John A. Vernon
537-562 Cost Considerations in the Treatment of Colorectal Cancer
by Frank G.A. Jansman & Maarten J. Postma & Jacobus R.B.J. Brouwers
563-576 Retrospective Economic and Outcomes Analyses Using Non-US Databases: A Review
by Lizheng Shi & Eric Q Wu & Meredith Hodges & Andrew Yu & Howard Birnbaum
577-590 A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma
by Ya-Chen Tina Shih & Josephine Mauskopf & Rohit Borker
591-603 The Use of Disease-Specific Outcome Measures in Cost-Utility Analysis: The Development of Dutch Societal Preference Weights for the FACT-L Scale
by Leida M. Lamers & Carin A. Uyl-de Groot & Ivonne Buijt
605-618 Direct and Indirect Costs Attributable to Alcohol Consumption in Germany
by Alexander Konnopka & Hans-Helmut Konig
619 Cost-Utility Analysis in China: Differences and Difficulties Compared with Developed Countries
by Liu Bao Peng & Chong Qing Tan & Xiao Min Wan & Wei Cui

2007, Volume 25, Issue 6

443-454 Reform of Prescription Drug Reimbursement and Pricing in the German Social Health Insurance Market: A Comparison of Three Scenarios
by Stefan Gress & Dea Niebuhr & Uwe May & Jurgen Wasem
455-466 Estimation, Power and Sample Size Calculations for Stochastic Cost and Effectiveness Analysis
by S.D. Walter & Amiram Gafni & Stephen Birch
467-479 A Systematic Review of Economic Evaluation Literature in Thailand: Are the Data Good Enough to be Used by Policy-Makers?
by Yot Teerawattananon & Steve Russell & Miranda Mugford
481-496 Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs: A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia
by Theodore Darkow & Henry J. Henk & Simu K. Thomas & Weiwei Feng & Jean-Francois Baladi & George A. Goldberg & Alan Hatfield & Jorge Cortes
497-509 Cost Effectiveness of Oseltamivir Treatment for Patients with Influenza-Like Illness Who Are at Increased Risk for Serious Complications of Influenza: Illustration for The Netherlands
by Maarten J. Postma & Annoesjka Novak & Huib W.K.F.H. Scheijbeler & Marlene Gyldmark & Marianne L.L. van Genugten & Jan C. Wilschut
511-521 Costs and Benefits of Direct-to-Consumer Advertising: The Case of Depression
by Adam E. Block
523-528 Building Bridges Between Academic Research and Policy Formulation: When Costing Less Means Costing More
by Amiram Gafni & Stephen Birch
528-532 Being Led Down the Wrong Garden PATH: the Importance of Knowledge and Facts for the Crossroads
by Ron Goeree & Daria O'Reilly & Jean-Eric Tarride & Jim Bowen & Gord Blackhouse & Kaitryn Campbell & Rob Hopkins & Morgan Lim & Lisa Patterson

2007, Volume 25, Issue 5

355-363 Replace Pharmaceutical Patents Now
by Earl L. Grinols & James W. Henderson
365-384 Health Utilities Using the EQ-5D in Studies of Cancer
by A. Simon Pickard & Caitlyn T. Wilke & Hsiang-Wen Lin & Andrew Lloyd
385-396 The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD): Responsiveness to Change and English Language Validation
by Peter Wahlqvist & Gordon H. Guyatt & David Armstrong & Alessio Degl'Innocenti & Diane Heels-Ansdell & Samer El-Dika & Ingela Wiklund & Carlo A. Fallone & Lisa Tanser & Sander Veldhuyzen van Zanten & Peggy Austin & Alan N. Barkun & Naoki Chiba & Holger J. Schunemann
397-411 Costs of a Community Pharmacist-Led Medicines Management Service for Patients with Coronary Heart Disease in England: Healthcare System and Patient Perspectives
by Anthony Scott & Michela Tinelli & Christine Bond
413-428 Economic Evaluation of Treatment Administration Strategies of Ganciclovir for Cytomegalovirus Retinitis in HIV/AIDS Patients in Thailand: A Simulation Study
by Kanlaya Teerawattananon & Saniorn Iewsakul & Chawewan Yenjitr & Somsanguan Ausayakhun & Watanee Yenjitr & Miranda Mugford & Yot Teerawattananon
429-442 Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model
by J. Alasdair Millar & Michael J. Millward

2007, Volume 25, Issue 4

267-268 Letter From the Commissioner's Office at the US FDA
by John A. Vernon
269-286 Measuring Patient-Reported Outcomes in Solid Organ Transplant Recipients: An Overview of Instruments Developed to Date
by Irina Cleemput & Fabienne Dobbels
287-308 The Economic Implications of Glaucoma: A Literature Review
by Jordana K. Schmier & Michael T. Halpern & Mechelle L. Jones
309-327 Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer
by Steven B. Zeliadt & David F. Penson
329-342 Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients: US Healthcare System Perspective
by Thomas E. Delea & Oleg Sofrygin & Simu K. Thomas & Jean-Francois Baladi & Pradyumna D. Phatak & Thomas D. Coates
343-351 Therapeutic Use of Granulocyte Colony-Stimulating Factors for Established Febrile Neutropenia: Effect on Costs from a Hospital Perspective
by Leon E. Cosler & Adi Eldar-Lissai & Eva Culakova & Nicole M. Kuderer & David Dale & Jeffrey Crawford & Gary H. Lyman
353 Book Review
by Adis International Limited

2007, Volume 25, Issue 3

181-185 Economic Evaluation and Decision Making: Reimbursing Trastuzumab in Early-Stage Breast Cancer
by Steven Simoens
187-199 Economic Evaluations of Cholesterol-Lowering Drugs: A Critical and Systematic Review
by Pearl D. Gumbs & Monique W.M. Verschuren & Aukje K. Mantel-Teeuwisse & Ardine G. de Wit & Anthonius de Boer & Olaf H. Klungel
201-208 Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases: The Limitations of Standard Economic Metrics as Exemplified by Fabry-Anderson Disease
by David F. Moore & Markus Ries & Evelyn L. Forget & Raphael Schiffmann
209-221 Do Drugs Reduce Utilisation of Other Healthcare Resources?
by Pierre-Yves Cremieux & Pierre Ouellette & Patrick Petit
223-237 Recombinant Erythropoietin for Chemotherapy-Related Anaemia: Economic Value and Health-Related Quality-of-Life Assessment Using Direct Utility Elicitation and Discrete Choice Experiment Methods
by Diego F. Ossa & Andrew Briggs & Emma McIntosh & Warren Cowell & Tim Littlewood & Mark Sculpher
239-251 Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients
by Danielle E.M. Brunenberg & Gwenn E.C. Wetzels & Patricia J. Nelemans & Carmen D. Dirksen & Johan L. Severens & Henri E.J.H. Stoffers & Jan S.A.G. Schouten & Martin H. Prins & Peter W. de Leeuw & Manuela A. Joore
253-266 Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada
by Daniel T. Grima & Melissa F. Thompson & Luc Sauriol

2007, Volume 25, Issue 2

89-90 Letter From the Commissioner's Office at the US FDA
by John A. Vernon
91-92 Is Medication Review by Pharmacists of Any Use?
by Arnold G. Zermansky & Nick Freemantle
93-106 Measuring Preferences for Cost-Utility Analysis: How Choice of Method May Influence Decision-Making
by Christine M. McDonough & Anna N.A. Tosteson
107-127 A `League Table' of Contingent Valuation Results for Pharmaceutical Interventions: A Hard Pill to Swallow?
by Tracey H. Sach & Richard D. Smith & David K. Whynes
129-142 Disease Burden of Overactive Bladder: Quality-of-Life Data Assessed Using ICI-Recommended Instruments
by Ramandeep Basra & Con Kelleher
143-154 Conjoint Analysis of French and German Parents' Willingness to Pay for Meningococcal Vaccine
by David Bishai & Roger Brice & Isabelle Girod & Aneta Saleh & Jenifer Ehreth
155-169 Acute/Subacute Herpes Zoster: Healthcare Resource Utilisation and Costs in a Group of US Health Plans
by Ralph P. Insinga & Robbin F. Itzler & James M. Pellissier
171-180 Home-Based Medication Review in Older People: Is it Cost Effective?
by Margaret Pacini & Richard D. Smith & Edward C.F. Wilson & Richard Holland

2007, Volume 25, Issue 1

1-2 Letter From the Commissioner's Office at the US FDA
by John A. Vernon
3-6 Rates and Probabilities in Economic Modelling: Transformation, Translation and Appropriate Application
by Rachael L. Fleurence & Christopher S. Hollenbeak
7-24 Reducing the Societal Burden of Depression: A Review of Economic Costs, Quality of Care and Effects of Treatment
by Julie M. Donohue & Harold Alan Pincus
25-37 Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to Antidepressants
by Judith E. Bosmans & Oscar H. Brook & Hein P.J. van Hout & Martine C. de Bruijne & Hugo Nieuwenhuyse & Lex M. Bouter & Wim A.B. Stalman & Maurits W. van Tulder
39-54 A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
by Dominic P. Tilden & Segundo Mariz & Gillies O'Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos
55-71 Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis
by Mark J.C. Nuijten & Wolfgang Wittenberg & Maximilian Lebmeier
73-88 Time Preferences for Health in Northern Tanzania: An Empirical Analysis of Alternative Discounting Models
by Bjarne Robberstad & John Cairns

2006, Volume 24, Issue 12

1169-1171 Acknowledgement
by Adis International Limited
1173-1177 Do Pharmacogenomic Tests Provide Value to Policy Makers?
by Ya-Chen Tina Shih & Lajos Pusztai
1179 Letter From the Commissioner's Office at the US FDA
by John A. Vernon
1181-1197 Assessing Generalisability in Model-Based Economic Evaluation Studies: A Structured Review in Osteoporosis
by Hege Urdahl & Andrea Manca & Mark J. Sculpher
1199-1220 Generic Health-Related Quality-of-Life Assessment in Children and Adolescents: Methodological Considerations
by Ulrike Ravens-Sieberer & Michael Erhart & Nora Wille & Ralf Wetzel & Jennifer Nickel & Monika Bullinger
1221-1232 Cost Effectiveness of Tumour Necrosis Factor-alpha Inhibitors as First-Line Agents in Rheumatoid Arthritis
by James R. Spalding & Joel Hay
1233-1248 Association of Co-Morbidities with Prescribing Patterns and Cost Savings: Olanzapine versus Risperidone for Schizophrenia
by Wei Yu & Xinhua S. Ren & Austin F. Lee & Lawrence Herz & Yu-Hui Huang & Lewis E. Kazis
1249-1272 Candesartan Cilexetil: A Pharmacoeconomic Review of its Use in Chronic Heart Failure and Hypertension
by Greg L. Plosker & Susan J. Keam
1273-1274 Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies
by Stuart Birks
1275-1276 The Authors' Reply
by J.M. Bos & M.J. Postma & L. Annemans

2006, Volume 24, Issue 11

1039-1042 Better Analysis for Better Decisions: Facing Up to the Challenges
by Michael F. Drummond & Mark J. Sculpher
1043-1053 Recent Developments in Decision-Analytic Modelling for Economic Evaluation
by Milton C. Weinstein
1055-1068 Using Value of Information Analysis to Prioritise Health Research: Some Lessons from Recent UK Experience
by Karl P. Claxton & Mark J. Sculpher
1069-1078 Utility Measurement in Healthcare: The Things I Never Got To
by George W. Torrance
1079-1086 Pharmacoeconomics and Pharmacoepidemiology: Curious Bedfellows or a Match Made in Heaven?
by Andrew H. Briggs & Adrian R. Levy
1087-1099 Analysis Sans Frontieres: Can We Ever Make Economic Evaluations Generalisable Across Jurisdictions?
by Mark J. Sculpher & Michael F. Drummond
1101-1119 `Lost in Translation': Accounting for Between-Country Differences in the Analysis of Multinational Cost-Effectiveness Data
by Andrea Manca & Andrew R. Willan
1121-1131 Information Created to Evade Reality (ICER): Things We Should Not Look to for Answers
by Stephen Birch & Amiram Gafni
1133-1142 Economic Evaluation and Decision Making in the UK
by Martin J. Buxton
1143-1156 Building Bridges Between Academic Research and Policy Formulation: The PRUFE Framework - an Integral Part of Ontario's Evidence-Based HTPA Process
by Ron Goeree & Leslie Levin
1157-1162 Economic Evaluations in the Canadian Common Drug Review
by Andreas Laupacis
1163-1168 Economic Evaluation in the US: What is the Missing Link?
by Peter J. Neumann & Sean D. Sullivan

2006, Volume 24, Issue 10

937-945 The Generalisability of Pharmacoeconomic Studies: Issues and Challenges Ahead
by James M. Mason & Anne R. Mason
947-952 QALYs: Are They Helpful to Decision Makers?
by Maurice McGregor & J. Jaime Caro
953-954 Should We Abandon QALYs as a Resource Allocation Tool?
by Sandeep Vijan
955-970 Therapeutic Options for the Prevention and Treatment of Postoperative Nausea and Vomiting: A Pharmacoeconomic Review
by Jean Lachaine
971-988 Single-Inhaler Combination Therapy for Asthma: A Review of Cost Effectiveness
by Manabu Akazawa & David A. Stempel
989-998 Disability and Quality of Life in Post-Traumatic Stress Disorder: Impact of Drug Treatment
by Soraya Seedat & Christine Lochner & Bavanisha Vythilingum & Dan J. Stein
999-1009 Hospitalisation Costs of Cystic Fibrosis
by Jonas Schreyogg & Helge Hollmeyer & Miriam Bluemel & Doris Staab & Reinhard Busse
1011-1020 The Initial Validation of a Markov Model for the Economic Evaluation of (New) Treatments for Rheumatoid Arthritis
by Paco M.J. Welsing & Johan L. Severens & Margriet Hartman & Anke M. van Gestel & Piet L.C.M. van Riel & Roland F.J.M. Laan
1021-1033 The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US
by Patrick W. Sullivan & Thomas W. Arant & Samuel L. Ellis & Heather Ulrich
1035-1038 Anticoagulation for Stroke Prevention: High Effectiveness, More Cost Benefit?
by Eduard Shantsila & Timothy Watson & Gregory Y.H. Lip

2006, Volume 24, Issue 9

833-836 US FDA Guidance: Apropos of PROs
by Paul Kind
837-844 Accuracy versus Transparency in Pharmacoeconomic Modelling: Finding the Right Balance
by David M. Eddy
845-853 The Value of Thinly Spread QALYs
by Duncan Mortimer
855-868 Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework: Some Considerations
by Emma McIntosh
869-890 Cost-of-Illness Studies: A Review of Current Methods
by Ebere Akobundu & Jing Ju & Lisa Blatt & C. Daniel Mullins
891-902 Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996-2003
by Yue-Chune Lee & Ming-Chin Yang & Yu-Tung Huang & Chien-Hsiang Liu & Sun-Bing Chen
903-915 Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia: Cost Effectiveness and Risk Sharing
by John H. Wlodarczyk & Leslie G. Cleland & Anne M. Keogh & Keith D. McNeil & Kate Perl & Robert G. Weintraub & Trevor J. Williams
917-925 Missing Data Imputation in Quality-of-Life Assessment: Imputation for WHOQOL-BREF
by Ting Hsiang Lin
927-929 Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes
by Andrew J. Palmer & Craig J. Currie
929-935 The Authors' Reply
by Adrian A. Bagust & Marc Evans & Sophie Beale & Philip Home & Andrew Perry & Murray Stewart & Arran Shearer & Alan Martin & Lisa Hulme & Andreas Liebl & Oliver Schoeffski & Anita Goertz & Javier Ampudia-Blasco & Belen Martinez-Lage & Isabel Perez Escolano & Gonzalo Paris

2006, Volume 24, Issue 8

727-742 Cost Effectiveness of Leukotriene Modifiers in Adults with Asthma
by Pamela C. Heaton
743-750 Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension: A Systematic Review of Economic Evidence
by Michelle Orme & Annabel Boler
751-765 A Comparative Review of Health-Related Quality-of-Life Measures for Use in HIV/AIDS Clinical Trials
by Darren J. Clayson & Diane J. Wild & Paul Quarterman & Isabelle Duprat-Lomon & Maria Kubin & Stephen Joel Coons
767-781 Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease
by Virginia L. Priest & Evan J. Begg & Sharon J. Gardiner & Christopher M.A. Frampton & Richard B. Gearry & Murray L. Barclay & David W.J. Clark & Paul Hansen
783-795 A Multi-Country Health Economic Evaluation of Highly Concentrated N-3 Polyunsaturated Fatty Acids in Secondary Prevention after Myocardial Infarction
by Mark Lamotte & Lieven Annemans & Pawel Kawalec & York Zoellner
797-814 Costs of Inflammatory Bowel Disease in Germany
by Renee Stark & Hans-Helmut Konig & Reiner Leidl
815-830 Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada
by Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette
831-832 National-Level Purchasing of Expensive Drugs is Increasing Pressure on the Hospital Drug Budget
by Slobodan M. Jankovic & Nebojsa Milivojevic

2006, Volume 24, Issue 7

627-629 NICE Says No to Inhaled Insulin: What Lessons Should We Learn?
by Nick Freemantle
631-642 Economic Models of Antiretroviral Therapy: Searching for the Optimal Strategy
by Fred J. Hellinger